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The total reimbursement for anti-diabetic drugs in U.S. Medic-
aid programs increased from $90.7 million in 1991 to $1.1
billion in 2005. The number of prescriptions increased dramat-
ically from 4.1 million in 1991 to 18.2 million in 2005. The cost
per prescription for brand-name drugs increased over time as
well. The relatively expensive drugs in 2005 were Actos ($169),
Avandia ($133), Avandamet ($150), Prandin($113), and Starlix
($103). The total number of prescriptions for the ﬁrst-generation
sulfonylureas dropped from 1.1 million in 1991 to 292,000 in
2005, while the number of prescriptions for other classes
increased over the years. For example, the number of prescrip-
tions for biguanides increased from 39,849 in 1995 to 5.7
million in 2005, the number of thiazolidinedione prescriptions
increased from 323,581 in 1997 to 4.5 million in 2005, and the
number of meglitinide prescriptions increased from 30,790 in
1998 to 425,516 in 2005. CONCLUSION: Increased expendi-
ture for oral anti-diabetic drugs was caused by both increased
price and utilization. When the generic drugs metformin, glip-
izide, and glyburide were introduced to the market, the use of
their brand-name counterparts decreased dramatically due to
Medicaid’s policies encouraging generic substitution.
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OBJECTIVES: The American Diabetes Association recommends
treating diabetes patients to a target hemoglobin A1c level of 7%
or less. Our objective was to examine the inﬂuence of A1c test
results on decisions to initiate exogenous insulin supplementa-
tion in Type 2 diabetes. METHODS: A database of clinical lab-
oratory results linked to health plan claims (MarketScan Lab)
was used to identify patients with a diagnosis of Type 2 diabetes.
Their ﬁrst A1c test result between July 2003 and June 2005 was
identiﬁed and patients were classiﬁed as at target (less than 7),
above target (7–9), or poorly controlled (>9). The study sample
was restricted to patients who had 6 months of claims history
prior to and 6 months after the index test, and who received only
oral antidiabetes therapy during the pre-test period. Addition of
insulin to the regimen within 6 months after the test was
assessed. RESULTS: A total of 4836 patients were identiﬁed,
including 2450 (51%) who were at target, 1567 (32%) above
target, and 819 (17%) poorly controlled. Insulin was added to
the regimen of 12.9% of patients with poor control, 4.3% of
those above target, and 1.5% of those at target (p < 0.00001).
Among poorly controlled patients insulin was added in 22.0%
of patients already on 3 oral medications, 12.6% of those with
2 oral medications, and 8.6% of those with 1 oral medication
(p < 0.001). A1c test result and prior oral medication use
remained signiﬁcant predictors of insulin supplementation after
controlling for demographic variation. CONCLUSION: High
levels of A1c indicating poor glycemic control led some patients
with Type 2 diabetes to initiate insulin supplementation, par-
ticularly those already receiving multiple oral medications.
However, poorly controlled patients were still most likely to
remain on oral therapy only, even if they were already using 3
or more medications.
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OBJECTIVES: The purpose of this study was to assess the
impact of patient and physician education on Hemoglobin A1c
(HbA1c) control in diabetes patients with concomitant hyper-
tension. METHODS: The analysis was based on a subset of
those enrolled in the Baltimore Partnership Programs to Reduce
CVD Disparities project, with one year of follow-up. Patients
and their physicians were randomly assigned to either interven-
tion or control group, in a 2X2 nested case control factorial
design. Patients and physicians participated in educational ses-
sions. We calculated the change in HbA1c value, from baseline,
to one year follow-up. Multiple regression was used to assess the
effects of interventions on HbA1c change adjusting for age, race,
gender and hypertension. RESULTS: Out of the study cohort of
114 patients, most were African American (96%) and female
(62%). Mean baseline HbA1c values were higher among males
vs. females (8.7% vs. 8.6%), African Americans vs. Caucasians
(8.7% vs. 8.15%), Intervention patients vs. control patients
(9.15% vs. 8.28%), and patients of Intervention vs. control
physicians (8.94% vs.8.33%). The drop in the HbA1c values
was greater among intervention patients (−0.6 vs. 0.2) and
patients of intervention physicians (−0.32 vs. 0.01). After con-
trolling for age, race, gender and hypertension, the drop in
HbA1c in the patient intervention group was greater than the
control and the drop in HbA1c in the patients of intervention
physicians was greater than the control though statistically non-
signiﬁcant. CONCLUSION: In this patient sample, greater drop
in HbA1c is seen among the intervention patients and patients
of Intervention physicians. These results highlight the inﬂuence
of patient and physician interventions supporting Diabetes
disease management programs.
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OBJECTIVES: The Diabetes Symptom Checklist-Revised
(DSCR) is a 34-item, 7-subscale instrument designed to provide
a comprehensive measure of diabetes-associated symptoms.
When evaluating antihyperglycemic medications in a clinical trial
however, only those symptoms affected by ﬂuctuations in
glycemic control (e.g., hyperglycemia) would be expected to
change. Therefore, the objective of this study was to validate the
DSC-R Cognitive Distress, Fatigue, Hyperglycemia, and Hypo-
glycemia subscales as individual measures of symptom groups to
be targeted in clinical trials of antihyperglycemic medications.
METHODS: In two clinical trials evaluating antihyperglycemic
medications (Study 1: insulin therapy in 137 patients with type
1 diabetes; Study 2: oral therapy in 150 patients with type 2 dia-
betes), participants were administered the DSC-R at several time
periods including screening, baseline and endpoint. To conﬁrm
the factorial validity of the subscales, a promax factor analysis
